Document:

f8k011113ex10i_carcharging.htm

Exhibit 10.1

 

 

March 14, 2013

 

Mr. William Fields

2083 Flintrock Trace

Austin, TX 78738

 

Re: Board of Directors Offer Letter Agreement

 

Dear Bill,

 

I am very pleased to offer you a position as a member of the Board of Directors (the “Board”) of Car Charging Group, Inc. (OTCQB: CCGI) (“CarCharging” or the “Company”).

 

Should you choose to accept this position as a member of the Board, this letter shall constitute an agreement between you and the Company (the “Agreement”) and contains all of the terms and conditions relating to the services you are to provide. This Agreement is based on the following terms and conditions:

 

	
Start Date:

	
The date your appointment is formally approved by the Board of Directors of the Company (the “Effective Date”) shall constitute your starting date.  You will serve as member of the Board until the annual meeting for the year in which your term expires or until your successor has been elected and qualified, subject however, to your prior death, resignation, retirement, disqualification or removal from office.

 

	
Term:

	
Your initial term shall be three (3) years.

 

	
Services:

	
You shall render services as a member of the Board (hereinafter your “Duties”).  During the term of this Agreement, you shall attend and participate in such number of meetings of the Board as regularly or specially called, but in any case no fewer than four (4) meetings per year.  You may attend and participate in each such meeting, via teleconference, videoconference or in person.  You shall consult with other members of the Board regularly and as necessary via telephone, electronic mail or other forms of correspondence.  You shall also participate in approximately four (4) conference calls for operational purposes with the Company’s management in any year.

 

	
Committees:

	
You acknowledge and agree that, in order to meet SEC and NYSE rules, you will be required to serve on one or more of the Board’s Audit Committee, Compensation Committee, and/or Nominating and Governance Committee, and that such committee assignments will be agreed between you and the Company, and that you will be compensated for service on any committee as provided herein.

 

	
Compensation:

	
During your term as a member of the Board, in consideration of your services, you will receive the following: (i) upon execution of this Agreement, 50,000 fully paid and nonassessable shares (the “Shares”) of Company restricted common stock (the “Common Stock”) and an option to purchase up to 12,000 shares of Common Stock at an exercise price per share equal to $0.01 above the closing price on the date of issuance; (ii) on each anniversary of the Effective Date, options to purchase up to 12,000 shares of Common Stock at an exercise price per share equal to $0.01 above the closing price on the date of issuance; (iii) options to purchase up to 5,000 shares of Common Stock for your attendance at any Company Board meeting at an exercise price equal to $0.01 above the closing price on the date of issuance; (iv) a nominal fee of $1,500 (the “Nominal Fee”) for each Board Meeting you attend and (v) should you become chairman of any committee of the Board, $1,500 per committee meeting you attend (the “Additional Fee”).

 

 

 

 

 

	
2 of 7

William Fields Offer Letter

 

	 	
At the option of the Company, the Nominal Fee and the Additional Fee may be paid in Company Common Stock, at a value of two times its cash value. All options given under this Agreement shall be non-cashless, shall vest after a period of two (2) years and shall expire five (5) years from the date of issue.

 

	
Sale Restrictions.

	
You hereby agree that you will not, without the prior written consent of the Company, offer, pledge, sell, contract to sell, hypothecate, lend, transfer or otherwise dispose of any of the shares which you own or have a right to acquire as of the date hereof (collectively, the “Lockup Shares”) for a period of six (6) months following the date you receive the Lockup Shares (the “Lockup Period”).  Following the expiration of the Lockup Period, you shall have the right, in the aggregate, to sell, dispose of or otherwise transfer the Lockup Shares without restriction, up to five percent (5%) of the total daily trading volume of the Company’s common stock.

 

Any subsequent issuance to and/or acquisition by you of Common Stock or options or instruments convertible into Common Stock shall be subject to the restrictions contained herein.

 

Until such time as you have sold all of the Lockup Shares, within five (5) business days of any sale, transfer or other transaction made by you with regard to the Company’s securities, you shall deliver to the Company a written statement detailing (i) the sale, transfer or other transaction giving rise to such written statement and (ii) your current holdings of the Company’s securities.

 

Permitted Transfers. Notwithstanding the foregoing restrictions on transfer, you may, at any time and from time to time, transfer the Lockup Shares (i) as bona fide gifts or transfers by will or intestacy, (ii) to any trust for your direct or indirect benefit or your immediate family, provided that any such transfer shall not involve a disposition for value, (iii) to a partnership which is the general partner of a partnership of which you are a general partner, or (iv) make a gift of to an organization exempt from taxation under Section 501(c)(3) of the Internal Revenue Code of 1986, as amended provided, that, in the case of any gift or transfer described in clauses (i), (ii), (iii) or (iv), each donee or transferee agrees in writing to be bound by the terms and conditions contained herein in the same manner as such terms and conditions apply to the undersigned so that in the aggregate, no more than the number of Lockup Shares allowable under this Agreement may be transferred on a given day, except in accordance with the terms hereof. For purposes hereof, “immediate family” means any relationship by blood, marriage or adoption, not more remote than first cousin.

 

CAR CHARGING GROUP, INC.

1691 MICHIGAN AVE., STE 601 ● MIAMI BEACH, FL 33139

PHONE: 305.521.0200 ● FAX: 305.521.0201

E-MAIL: INFO@CARCHARGING.COM WWW.CARCHARGING.COM

 

 

 

 

 

	
3 of 7

William Fields Offer Letter

 

	  	
Ownership. Until such time as you have sold the shares in question, you shall retain all rights of ownership in the Lockup Shares, including, without limitation, voting rights and the right to receive any dividends that may be declared in respect thereof.

 

The Company is hereby authorized to disclose the existence of this Agreement to its transfer agent and such transfer agent shall only release shares in accordance with the limitations contained herein. The Company and its transfer agent are hereby authorized to decline to make any transfer of the Lockup Shares if such transfer would constitute a violation or breach of this Agreement.

 

	
Expenses:

	
The Company agrees to reimburse all of your travel and other reasonable documented expenses relating to your attendance at meetings of the Board.  In addition, the Company agrees to reimburse you for reasonable expenses that you incur in connection with the performance of your duties as a director of the Company.

 

	
Indemnification:

	
You will receive indemnification as a director of the Company to the maximum extent extended to directors of the Company generally, as set forth in the Company’s Certificate of Incorporation and bylaws.

 

	
D&O Insurance:

	
During your term as a member of the Board, the Company shall include you as an insured under an officers and directors insurance policy, with current coverage of five million dollars ($5,000,000) for all losses in the aggregate, including defense costs.

 

	
Service For Others:

	
You will be free to represent or perform services for other persons during the term of this Agreement.  However, you agree that you do not presently perform and do not intend to perform, during the term of Agreement, similar Duties, consulting or other services for companies whose businesses whose businesses are or would be, in any way, competitive with the Company (except for companies previously disclosed by you to the Company in writing).  Should you propose to perform similar Duties, consulting or other services for any such company, you agree to notify the Company in writing in advance (specifying the name of the organization for whom you propose to perform such services) and to provide information to the Company sufficient to allow it to determine if the performance of such services would conflict with areas of interest to the Company.

 

CAR CHARGING GROUP, INC.

1691 MICHIGAN AVE., STE 601 ● MIAMI BEACH, FL 33139

PHONE: 305.521.0200 ● FAX: 305.521.0201

E-MAIL: INFO@CARCHARGING.COM WWW.CARCHARGING.COM

 

 

 

 

 

	
4 of 7

William Fields Offer Letter

 

	
No Assignment:

	
Because of the personal nature of the services to be rendered by you, this Agreement may not be assigned by you without the prior written consent of the Company.

 

	

Confidential

Information:

	
In consideration of your access to the premises of the Company and/or you access to certain Confidential Information of the Company, in connection with your business relationship with the Company, you hereby represent and agree as follows:

 

Definition. For purposes of this Agreement the term “Confidential Information” means:

 

i. Any information which the Company possesses that has been created, discovered or developed by or for the Company, and which has or could have commercial value or utility in the business in which the Company is engaged; or

 

ii. Any information that is related to the business of the Company and is generally not known by non-Company personnel.

 

iii. By way of illustration, but not limitation, Confidential Information includes trade secrets and any information concerning products, processes, formulas, designs, inventions (whether or not patentable or registrable under copyright or similar laws, and whether or not reduced to practice), discoveries, concepts, ideas, improvements, techniques, methods, research, development and test results, specifications, data, know-how, software, formats, marketing plans, and analyses, business plans and analyses, strategies, forecasts, customer and supplier identities, characteristics and agreements.

 

Exclusions. Notwithstanding the foregoing, the term Confidential Information shall not include:

 

i. Any information which becomes generally available to the public other than as a result of a breach of the confidentiality portions of this Agreement, or any other agreement requiring confidentiality between the Company and you;

 

ii. Information received from a third party in rightful possession of such information who is not restricted from disclosing such information; and

 

iii. Information known by you prior to receipt of such information from the Company, which prior knowledge can be documented.

 

CAR CHARGING GROUP, INC.

1691 MICHIGAN AVE., STE 601 ● MIAMI BEACH, FL 33139

PHONE: 305.521.0200 ● FAX: 305.521.0201

E-MAIL: INFO@CARCHARGING.COM WWW.CARCHARGING.COM

 

 

 

 

 

	
5 of 7

William Fields Offer Letter

 

	 	
Documents. You agree that, without the express written consent of the Company, you will not remove from the Company's premises, any notes, formulas, programs, data, records, machines or any other documents or items which in any manner contain or constitute Confidential Information, nor will you make reproductions or copies of same. In the event you receive any such documents or items by personal delivery from any duly designated or authorized personnel of the Company, you shall be deemed to have received the express written consent of the Company. In the event that you receive any such documents or items, other than through personal delivery as described in the preceding sentence, you agree to inform the Company promptly of your possession of such documents or items. You shall promptly return any such documents or items, along with any reproductions or copies to the Company upon the Company's demand, upon termination of this Agreement, or upon your termination or Resignation, as defined herein.

 

No Disclosure. You agree that you will hold in trust and confidence all Confidential Information and will not disclose to others, directly or indirectly, any Confidential Information or anything relating to such information without the prior written consent of the Company, except as maybe necessary in the course of your business relationship with the Company. You further agree that you will not use any Confidential Information without the prior written consent of the Company, except as may be necessary in the course of your business relationship with the Company, and that the provisions of this paragraph (d) shall survive termination of this Agreement.

 

	

Termination and

Resignation:

	
Your membership on the Company’s Board may be terminated for any or no reason at a meeting called for the purpose of the election of directors by a vote of the stockholders holding at least a majority of the shares of the Company’s issued and outstanding shares entitled to vote. Your membership on a Board committee may be terminated for any or no reason at any meeting of the Board by or by written consent of, a majority of the Board at any time. You may also terminate your membership on the Board or on a committee for any or no reason by delivering your written notice of resignation to the Company (“Resignation”), and such Resignation shall be effective upon the time specified therein or, if no time is specified, upon receipt of the notice of resignation by the Company. Upon the effective date of the termination or Resignation, your right to compensation hereunder will terminate subject to the Company's obligations to pay you any cash compensation (or equivalent value in Company Common Stock) that you have already earned and to reimburse you for approved expenses already incurred in connection with your performance of your Duties as of the effective date of such termination or Resignation.

 

	
Governing Law:  

	
All questions with respect to the construction and/or enforcement of this Agreement, and the rights and obligations of the parties hereunder, shall be determined in accordance with the law of the State of Nevada applicable to agreements made and to be performed entirely in the State of Nevada.

 

CAR CHARGING GROUP, INC.

1691 MICHIGAN AVE., STE 601 ● MIAMI BEACH, FL 33139

PHONE: 305.521.0200 ● FAX: 305.521.0201

E-MAIL: INFO@CARCHARGING.COM WWW.CARCHARGING.COM

 

 

 

 

	
6 of 7

William Fields Offer Letter

 

	

Entire Agreement;

Amendment;

Waiver;

Counterparts:  

	
This Agreement expresses the entire understanding with respect to the subject matter hereof and supersedes and terminates any prior oral or written agreements with respect to the subject matter hereof.  Any term of this agreement may be amended and observance of any term of this agreement may be waived only with the written consent of the parties hereto.  Waiver of any term or condition of this agreement by any party shall not be construed as a waiver of any subsequent breach or failure of the same term or condition or waiver of any other term or condition of this agreement.  The failure of any party at any time to require performance by any other party of any provision of this Agreement shall not affect the right of any such party to require future performance of such provision or any other provision of agreement.  This Agreement may be executed in separate counterparts each of which will be an original and all of which taken together will constitute one and the same agreement, and may be executed using facsimiles of signatures, and a facsimile of a signature shall be deemed to be the same, and equally enforceable, as an original of such signature.

 

CONTINUED ON NEXT PAGE

 

CAR CHARGING GROUP, INC.

1691 MICHIGAN AVE., STE 601 ● MIAMI BEACH, FL 33139

PHONE: 305.521.0200 ● FAX: 305.521.0201

E-MAIL: INFO@CARCHARGING.COM WWW.CARCHARGING.COM

 

 

 

 

 

	
7 of 7

William Fields Offer Letter

 

This Agreement sets forth the complete terms of your service on the Board.  Nothing in this Agreement should be construed as an offer of employment.  If the foregoing terms are agreeable, please indicate your acceptance by signing in the space provided below and returning this Agreement to the Company.

 

Sincerely,

 

By:  /s/ Michael D. Farkas                             

        Michael D. Farkas

Chief Executive Officer

 

Accepted and Agreed:

 

Signature: /s/ William Fields                          

 

Name:       William Fields

 

Date:         12/18/12                                          

CAR CHARGING GROUP, INC.

1691 MICHIGAN AVE., STE 601 ● MIAMI BEACH, FL 33139

PHONE: 305.521.0200 ● FAX: 305.521.0201

E-MAIL: INFO@CARCHARGING.COM WWW.CARCHARGING.COMf10q0113ex10iii1_scivanta.htm

EXHIBIT 10.3.1

 

First Addendum to the Amended and Restated Technology License Agreement

 

between

 

The Research Foundation for State University of New York

 

for and on behalf of University at Buffalo

 

and

 

Donald D. Hickey, M.D.

 

and

 

 Clas E. Lundgren, M.D., Ph.D.

 

and

 

Scivanta Medical Corporation

 

This First Addendum (this “First Addendum”) to the Amended and Restated Technology License Agreement, entered into as of the 14th day of March, 2013 (the “First Addendum Effective Date”), is by and among The Research Foundation for State University of New York, for and on behalf of University at Buffalo, a non-profit corporation organized and existing under the laws of the State of New York (the “Foundation”), Donald D. Hickey, M.D. (“Hickey”), Clas E. Lundgren, M.D., Ph.D. (a/k/a Claes Lundgren and referenced herein as “Lundgren”) and Scivanta Medical Corporation (formerly Medi-Hut Co., Inc.), a corporation duly organized under the laws of the State of Nevada, and having its principal place of business at 215 Morris Avenue, Spring Lake, New Jersey 07762 (“Licensee”).  Foundation, Hickey and Lundgren will be collectively referenced herein as “Licensor.”  Capitalized terms used herein, but not otherwise defined herein, shall have such meanings as given to such terms in the Technology License Agreement, as such term is defined below.

 

WHEREAS, Licensor and Licensee entered into an exclusive Amended and Restated Technology License Agreement on February 14, 2011 (the “Technology License Agreement”), to facilitate the development and commercialization of certain technology owned by Licensor so that this technology may be utilized to the fullest extent for the benefit of Licensee, Licensor, the inventor(s) and the public; and

 

WHEREAS, Licensor and Licensee desire to modify the Technology License Agreement for the mutual benefit of both parties;

 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties agree as follows:

 

1.           The modifications of the Technology License Agreement herein will be effective as of the First Addendum Effective Date and will remain in effect for the duration of the Technology License Agreement unless further modified in writing by the parties hereto.

 

  

1

  

 

2.           Section 2.7 will be added to the Technology License Agreement as follows:

2.7           Intellectual Property Assignment.  Concurrent with the execution of the First Addendum, Licensee will execute an intellectual property assignment to Licensor of any and all Licensee Improvements made, conceived, reduced to practice or fixed in a tangible medium by Licensee or its consultants, suppliers or contractors at any time after the 10th day of November, 2006.  Thereafter such intellectual property will be considered Licensor Technology under the Technology License Agreement.

 

3.           Section 3.10 of the Technology License Agreement is hereby deleted in its entirety and replaced with the following:

 

3.10         Cash Payment.  Licensee will pay Hickey a first cash payment of $50,000 on or before a date that is thirty (30) days after the closing of any single financing round of at least $3,000,000 or any series of financing rounds within a six (6) month period totaling at least $3,000,000.  Licensee will pay Hickey a second cash payment of $55,000 on or before the date that is thirty (30) days after the first commercial sale of a Licensed Product by the Licensee.  If the Licensee fails to make the payment pursuant to this Section 3.10 on or before the due date, then interest will accrue on any outstanding balance at a rate that is equal to the lesser of the maximum rate allowed by law or 1.5% per month.

4.           Section 3.12 will be added to the Technology License Agreement as follows:

 

3.12         Second Stock Grant.  Licensee will issue shares of Common Stock to the Licensor equal to $130,000 on the date the Company files for approval to market and sell a Licensed Product in a Major Market Country (defined below).  The number of shares of Common Stock to be issued to the Licensor will be calculated based on the Market Price of the Common Stock.  The Market Price is the closing price of the Common Stock on the domestic securities market on which the Common Stock may at the time be listed, averaged over a period of ten (10) trading days in which the stock traded immediately preceding the day as of which the “Market Price” is being determined.  The shares of Common Stock to be issued to the Licensor shall be allocated as follows: (a) 57% to the Foundation; (b) 23% to Hickey; and (c) 20% to Lundgren.  Each certificate representing the shares of Common Stock to be issued pursuant to this Section 3.12 will contain a restrictive legend on transfer and the Licensee has no obligation to register any of the shares of Common Stock under the Securities Act of 1933.

 

5.           Section 3.13 will be added to the Technology License Agreement as follows:

 

3.13         Third Stock Grant.  Licensee will issue shares of Common Stock to the Licensor equal to $160,000 on the date of the Company receives approval to market and sell a Licensed Product in a Major Market Country.  The number of shares of Common Stock to be issued to the Licensor will be calculated based on the Market Price of the Common Stock.  The shares of Common Stock to be issued to the Licensor shall be allocated as follows: (a) 57% to the Foundation; (b) 23% to Hickey; and (c) 20% to Lundgren.  Each certificate representing the shares of Common Stock to be issued pursuant to this Section 3.12 will contain a restrictive legend on transfer and the Licensee has no obligation to register any of the shares of Common Stock under the Securities Act of 1933.

 

  

2

  

 

6.           Section 4.1 of the Technology License Agreement is hereby deleted in its entirety and replaced with the following:

 

4.1           Licensee will use commercially reasonable efforts to commercialize and market Licensed Products as soon as practicable and in accordance with the milestone events set forth herein.  For purposes of this Agreement, the U.S., EU member countries, India, China, Brazil or Russia will be referred to individually as a “Major Market Country” or in groups of two or more as “Major Market Countries”.

7.           Section 4.2 of the Technology License Agreement is hereby deleted in its entirety and replaced with the following:

4.2           Unless there is “good reason” that such milestones cannot be reached with commercially reasonable efforts, Licensee undertakes to reach the following milestones in the timeframes set forth below:

 

	
  

	
(a)

	
On or before December 31, 2014, Licensee will, on its own or through a Sublicensee, commence a human clinical trial in at least one Major Market Country.

 

	
  

	
(b)

	
On or before December 31, 2016, Licensee will, on its own or through a Sublicensee, make a first commercial sale in at least two Major Market Countries.

 

	
  

	
(c)

	
Within twenty-four (24) months of completing the due diligence milestone in Section 4.2 (b) (i.e. making a first commercial sale in at least two Major Market Countries) Licensee will, on its own or through a Sublicensee, make a first commercial sale in at least two additional Major Market Countries.

As used herein, the term “good reason” will include:

 

	
  

	
1.

	
Events of force majeure bearing on the ability of Licensee to make, use or sell the device in the respective jurisdiction(s), including, but not limited to, unavailability of raw materials, commercial embargo, custom restrictions, state of war or similar political conflicts;

 

	
  

	
2.

	
The performance of the device in such a fashion that it is deemed to be dangerous or to incur undo risk for the user or patient or is medically unreliable;

 

	
  

	
3.

	
A determination by a governmental agency that the device will require clinical trials that reasonably cannot be completed before the milestone is reached;

 

	
  

	
4.

	
A challenge, claim, suit or interference to the Patent Rights or division of a patent that raises a significant commercial risk unless resolved;

 

  

3

  

 

	
  

	
5.

	
A determination that the device will require the filing of a PMA (by FDA in the U.S., or by similar determination by a governing agency in another jurisdiction) or that FDA has amended the requirements for approval as a 510(k) device;

 

	
  

	
6.

	
The revelation of facts concerning the state of development of the device, the clinical or biological results pertaining thereto, the ownership of the device or other significant facts bearing on the commercial viability of the device, which are contrary to or in conflict with the statements and/or representations of the Licensor or its agents concerning the device; or

 

	
  

	
7.

	
Adverse events or other clinical results suggesting a change in design or manufacture.

 

Except with respect to the occurrence of the events set forth in either 4 or 6 above, in the event of failure to meet the milestones for “good reason”, Licensee and Licensor will negotiate in good faith to amend the milestones, taking into account the “good reason” event that has occurred, in order to establish a revised set of commercially reasonable milestones and timeframes to be met by Licensee going forward.

In the event that: (i) a challenge, claim, suit interference to the Patent Rights that raises a significant commercial risk unless resolved, or is incapable of being resolved, or (ii) the revelation of facts concerning the state of development of the device, the clinical or biological results pertaining thereto, the ownership of the device or other significant facts bearing on the commercial viability of the device, which are contrary to or in conflict with the statements and/or representations of the Licensor or its agents concerning the device, Licensee will have the right to terminate this Agreement in accordance with Section 10.3.

8.           Section 4.3 of the Technology License Agreement is hereby deleted in its entirety and replaced with the following:

4.3           The Foundation (on behalf of the Licensors) will have the right to request a quarterly meeting with the Licensee, including as appropriate representatives from each of the catheter, software, hardware and clinical trial vendors involved in the development and testing of Licensed Products, to brief the Licensors on the status of product development and related clinical trials for the Licensed Product.  The meetings will be conducted via teleconference.  This right of the Licensors will expire upon the Licensee’s submission of an application for approval of the Licensed Product to the FDA.

9.           Section 4.4 of the Technology License Agreement is hereby deleted in its entirety and replaced with the following:

 

4.4           The Foundation is granted the right to have one person receive all written information provided to the Licensee’s board of directors, in conjunction with a meeting of the Licensee’s board of directors, which pertains to the Licensed Products.  The person designated by the Foundation will be subject to the approval of the Licensee, which approval will not be unreasonably withheld.  The Licensee approves Jeffrey A. Dunbar, or his successor at the Foundation, as the Foundation’s designee to receive the information.  This right of the Foundation will expire upon the Licensee receiving FDA approval to market the Licensed Product in the U.S.

 

10.         Other than as specifically modified in this First Addendum, all other terms, conditions and covenants of the Technology License Agreement shall remain in full force and effect.

 

----SIGNATURE PAGE FOLLOWS----

 

  

4

  

IN WITNESS WHEREOF, the undersigned duly authorized representatives of the parties have executed this First Addendum, effective as of the First Addendum Effective Date.

 

	
SCIVANTA MEDICAL CORPORATION

	 	 	
THE RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK

	 	 
	 	 	 	 	 	 	 	 
	
By:

	
/s/ David R. LaVance

	 	 	
By:

	
/s/ Woodrow W. Maggard

	 	 
	 	
David R. LaVance

	 	
  

	 	
Woodrow W. Maggard

	 	 
	 	 	 	 	 	 	 	 
	Title: 	
President and Chief Executive Officer

	 	 	Title: 	
Associate Vice Provost, STOR

	 	 
	 	 	 	 	 	 	 	 
	
DONALD D. HICKEY, M.D.

	 	 	
CLAS E. LUNDGREN, M.D., Ph.D.

	 	 
	 	 	 	 	 	 	 
	
By:

	
/s/ Donald D. Hickey

	 	 	
By:

	
/s/ Clas E. Lundgren

	 	 
	 	
Donald D. Hickey, M.D.

	 	 	 	
Clas E. Lundgren, M.D., Ph.D.

	 	 

 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]